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Amyloid betaLoss of synapses and synaptic damage are the best correlates of cognitive decline identiﬁed in patients with
Alzheimer's disease (AD), and mitochondrial oxidative damage and synaptic pathology have been identiﬁed
as early events in the progression of AD. The progressive accumulation of amyloid beta (Aβ) in synapses and
synaptic mitochondria are hypothesized to cause synaptic degeneration and cognitive decline in patients with
AD. However, the precise mechanistic link between Aβ andmitochondria is not well understood. The purpose
of this study was to better understand the effects of Aβ on mitochondrial axonal transport and synaptic
alterations in AD. Using mouse hippocampal neurons and Aβ25–35 peptide, we studied axonal transport of
mitochondria, including mitochondrial motility, mitochondrial length and size, mitochondrial index per
neurite, and synaptic alterations of the hippocampal neurons. In the PBS-treated neurons, 36.4±4.7% of the
observedmitochondria weremotile, with 21.0±1.3%moving anterograde and 15.4±3.4%moving retrograde
and the average speed of movement was 12.1±1.8 μm/min. In contrast, in the Aβ-treated neurons, the
number of motile mitochondria were signiﬁcantly less, at 20.4±2.6% (Pb0.032), as were those moving
anterograde (10.1±2.6%, Pb0.016) relative to PBS-treated neurons, suggesting that the Aβ25–35 peptide
impairs axonal transport of mitochondria in AD neurons. In the Aβ-treated neurons, the average speed of
motile mitochondria was also less, at 10.9±1.9 μm/min, and mitochondrial length was signiﬁcantly
decreased. Further, synaptic immunoreactivity was also signiﬁcantly less in the Aβ-treated neurons relative to
the PBS-treated neurons, indicating that Aβ affects synaptic viability. These ﬁndings suggest that, in neurons
affected by AD, Aβ is toxic, impairs mitochondrial movements, reduces mitochondrial length, and causes
synaptic degeneration.imer's disease; ATP, adenosine
tochondrial ﬁssion 1
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Alzheimer's disease (AD) is the most common neurodegenerative
disorder in the aged population. It is characterized by the progressive
decline of memory, decline in cognitive functions such as memory,
and changes in behavior and personality [1]. It is a major health
concern in society, especially because half of individuals 85 years of
age and older are expected to develop AD [2]. AD is associated with
multiple cellular changes in the brain, including the loss of synapses/
synaptic pathology, mitochondrial structural/functional abnormali-
ties, inﬂammatory responses, extracellular amyloid beta (Aβ) depos-
its, and intracellular neuroﬁbrillary tangles [1,3–10]. Among thesechanges, mitochondrial oxidative damage and synaptic pathology are
reported as early events in AD progression [11–15].
In AD, Aβ is a major component of neuritic plaques found in brain
regions known to be responsible for learning and memory. Aβ, the
39–43 amino acid residue protein, is generated by the proteolysis of
Aβ precursor protein (AβPP) by the sequential enzymatic actions of β-
secretase, and γ secretase. In AD, levels of Aβ are steady-state and are
controlled by the production, the clearance, and the degradation of
Aβ. Decreased clearance of Aβ or the overproduction of Aβ may lead
to an accumulation of Aβ in subcellular compartments, including
synapses and mitochondria, and may impair functions of subcellular
organelles and damage neurons [4,5,16]. Thus, agents or drugs
capable of increasing the clearance or decreasing the production of
Aβ may be important therapeutic strategies in preventing AD
development and progression.
Several researchers have reported that Aβ is responsible for
damaging mitochondria and synapses in neurons affected by AD [17–
24]. Monomeric and oligomeric forms of Aβ have been found in
mitochondrial membranes and to interact with mitochondrial
proteins, induce free radical production, alter mitochondrial enzymes,
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(ATP) production, and damage mitochondria [17–19,24–26]. Al-
though these results clearly associate Aβwith subcellular components
such as mitochondria, the precise link between Aβ and mitochondria
is not clear and how Aβ damages mitochondria is also not well
understood.
Mitochondrial shape and structure are maintained by mitochon-
drial ﬁssion and fusion [27–29]. Fission and fusion mechanisms are
equally balanced in healthy neurons. Mitochondria alter their shape
and size to move, through mitochondrial trafﬁcking, from the cell
body to the axons, dendrites and synapses via anterograde fashion,
and back to the cell body via retrograde manner [30]. Synapses are the
sites of high-energy demand. Mitochondria supply energy to
synapses, which is required for neural communications and several
synaptic functions, including the release of neurotransmitters,
synaptic vesicles between pre- and post-synaptic neurons. In a
healthy neuron, abundant numbers of healthy, functionally active
mitochondria are present at synapses, whereas in diseased neurons,
such as in AD-affected neurons, small numbers of defective mito-
chondria are present [31]. In the AD neuron, Aβ accumulates in the
mitochondria, induces free radical production, and activates the two
mitochondrial ﬁssion proteins dynamin-related protein 1 (Drp1) and
mitochondrial ﬁssion 1 (Fis1) [29]. Activated Drp1 and Fis1 have been
associated with excessive fragmentation of mitochondria that may
not move to synapses and do not supply the necessary ATP at nerve
terminals. Further, these defective mitochondria may not be able to
participate in mitochondrial fusion, may not be able to synthesize
healthy mitochondria, and may, ultimately, prematurely die. The
continual production of excessive numbers of defective mitochondria
in neurons may ultimately damage synapses and cause synaptic
neurodegeneration [29,31].
Using electron and confocal microscopy, gene expression analy-
sis, and biochemical methods, we treated mouse neuroblastoma
(N2a) cells with the Aβ25–35 peptide, and studied mitochondrial
structure and function; expressions of the ﬁssion genes Drp1 and Fis1
and the 3 fusion genes Mfn1, Mfn2, and Opa1; and neurite outgrowth
in [32]. In the neurons treated with only Aβ, we found increased
expressions of ﬁssion genes and decreased expressions of fusion
genes, indicating abnormal mitochondrial dynamics in neurons
treated with Aβ. Our immunocytochemistry of N2a cells treated
with Aβ revealed increased immunoreactivity of Drp1 and Fis1,
suggesting that Aβ elevates ﬁssion genes and fragments mitochon-
dria. Electronmicroscopy of the N2a cells incubatedwith Aβ revealed
a signiﬁcantly increased number of defective mitochondria, indicat-
ing that Aβ fragments mitochondria. Biochemical analysis revealed
Aβ in association with defective mitochondria. Neurite outgrowth
was signiﬁcantly decreased in those N2a cells that we incubatedwith
Aβ, indicating that Aβ affects neurite outgrowth.
In the research reported here, we sought to determine the effects
of Aβ on axonal transport of mitochondria in mouse hippocampal
neurons. We measured the total number of mitochondria, the length
and size of mitochondria, the mitochondrial index (length of the
mitochondria per neurite length), and the synaptic immunoreactivity
of AD neurons treated with the Aβ25–35 peptide compared to control
neurons (Aβ35–25) and those treated with the vehicle (PBS).
2. Materials and methods
2.1. Neuronal culture
Hippocampal neurons were cultured, as previously described [32].
Brieﬂy, hippocampi were dissected from C57BL/6 day 1 pups in room
temperatureHABG(HibernateEmedium[BrainBits, LLC] supplemented
with 1X B-27 [Invitrogen] and 0.5 mM glutamine [Invitrogen, CA]). The
tissues were dissociated with 2 mg/ml papain at 30 °C for 30 min in a
dissociation medium (Hibernate E medium without Ca++, supplemen-tedwith 0.5 mMglutamine). Digested tissuewas triturated, using aﬁre-
polished, silicon-coated Pasteur pipette in 2 ml HABG. Non-dissociated
tissue was allowed to settle for 5 min, after which time the supernatant
was passed through a 70-µm nylonmesh, into a 50-mL conical tube and
centrifuged for 2 min at 200×g. The pellet was gently resuspended in a
maintenance medium (Neurobasal A medium [Invitrogen, CA] supple-
mentedwith 1×B-27minus antioxidants, and0.5 mML-glutamine) and
plated onto a poly-D-lysine (Sigma-Aldrich)-coated, chambered cover-
glass (Nunc). The medium was completely replaced after 1 h, and then
half of the medium was replaced every 3 days.
2.2. Time lapse photography of mitochondrial motility and data analysis
Mitochondria were labeled by transfecting pDsRed2-mito (Clon-
tech) into the hippocampal neurons at day 2 (DIV) with lipofectamine
2000 (Invitrogen), according to the manufacturer's protocol. DsRed-
labeled neuronal mitochondria were observed in cultures up to
21 days after transfection (data not shown). Aβ25–35, Aβ35–25
(control) peptides were dissolved in 1× PBS. To increase the toxicity
of Aβ peptide, we incubated Aβ25–35, and Aβ35–25 (control) peptides at
37 °C for overnight, and this overnight incubation is expected to
convert monomeric Aβ to oligomeric Aβ. We treated neurons with
20 μM Aβ25–35 (oligomeric) Aβ35–25 (control), and a vehicle (PBS) at
10 DIV and then imaged 24 h later. Axonal processes were determined
by morphological characteristics. Axons were identiﬁed as processes
stemming from the soma that are two to three times longer than other
processes [32,33]. Recordings were made on axonal segments about
20–100 μm from the soma. Series of time-lapse images were captured
every 5 s, using a Leica SP5 AOBS confocal microscope with a heated
37 °C, 5% CO2 controlled stage for a total of 5 min. Z-stacks for each
time point were collapsed to maximum projections, and the time
series were archived as avi ﬁles. ImageJ software, with a Mulitple
Kymograph plug-in, was used to analyze the avi ﬁles. Mitochondrial
movements (direction and speed) were determined from the
kymographic images. Mitochondria were considered stationary if
they did not move more than 2 μmduring the entire recording period.
Each series of images was recorded for at least three randomly
selected Ds-Red-mito labeled cells per culture and four independent
cultures per condition.
2.3. Mitochondrial content of neurites
After imaging the mitochondria in the neuronal cultures, the
cultures were ﬁxed with 4% paraformaldehyde for 5 min at room
temperature and then washed with PBS. The plastic chambers were
carefully removed, and the coverslips were mounted on slides with a
ProLong Gold mounting medium. Images of cell bodies with neurites
extending at least 100 μm were collected, using a Leica SP5 AOBS
confocal microscope with a 63× objective. GFP and Ds-Red were
analyzed using measurement tools in ImageJ to determine the neurite
mitochondrial index, the average mitochondrial length, and the
number of mitochondria (per neurite length). Data were collected
from at least six cells per culture and four independent cultures per
condition.
2.4. Immunoﬂuorescence analysis of synaptic proteins
To determine the toxicity of Aβ in hippocampal neurons, we
performed immunocytochemical analysis of Drp1with mitochon-
dria-encoded protein Cytochrome b (Cyt. B), and synaptophysin,
which is marker for AD, with microtubule associated protein 2
(MAP2). Brieﬂy, we plated cells on 13-mm round coverslips coated
with poly-D-lysine contained within wells of a 24-well plate. After
treatment, the medium was removed, and cells were ﬁxed with 4%
paraformaldehyde in PBS for 10–15 min at room temperature.
Coverslips were washed with PBS, and cell membranes were
Fig. 1. Amyloid beta treatment reduces mitochondrial movements. Axons from mature
hippocampal neurons transfected with DsRed-mito and GFP, then treated for 24 h with
vehicle, Aβ, or reverse peptide were imaged to evaluate mitochondrial movements.
Total proportion of moving mitochondria, proportion of mitochondria moving
anterograde, and proportion of mitochondria moving retrograde were calculated (A).
The speed of motion was also calculated for all moving mitochondria (B). Calculations
were based on analysis of kymographs. Representative kymographs are shown for the
three experimental groups (C). N=4 independent cultures. *pb0.05 compared to
vehicle treated, and statistical variation is shown as mean±SE.
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time a blocking solution was applied (2% normal goat serum, 1% BSA
in PBS). All subsequent incubations were carried out in a humidiﬁed
environment. Samples were blocked for 2 h at room temperature and
then incubatedwith a primary antibody diluted in a blocking solution
overnight at 4 °C. Drp1 (1:200, rabbit polyclonal, Novus Biologicals,
Inc.), and synaptophysin (1:200, mouse monoclonal, Millipore/
Chemicon, Temecula, CA) were probed. After cells were incubated
with the primary antibody, cells were washed three times with PBS
and then incubated with either goat–anti-rabbit-Alexa488 or goat–
anti-mouse-Alexa568 (both 1:500, Invitrogen/Molecular Probes) for
2 h at room temperature. For co-labeling with Cyt. B (1:50, mouse
monoclonal, Invitrogen) or MAP2 (1:1000, rabbit polyclonal, Milli-
pore), cells were then incubated with the second primary antibody
for 3 h at room temperature. After washing three times with PBS,
coverslips were incubated with the corresponding secondary
antibody for 2 h at room temperature. Antibody was removed, and
DAPI (600nM in PBS) was added to the cells for 5 min. Cells were
washed three times in PBS, and then coverslips were mounted on
slides using a ProLong Gold antifade mounting reagent (Invitrogen).
Cells were imaged, using a Zeiss Axioskop 40 FL microscope.
2.5. Statistical analysis
Data from independent cultures were compared, using a two-
tailed, unpaired student's t-test with signiﬁcance level set at p≤0.05.
3. Results
3.1. Mitochondrial motility is less after Aβ treatment
To determine the effect of Aβ peptide onmitochondrial transport, we
incubated hippocampal neurons with 20 μM Aβ25–35, Aβ35–25 (control),
or PBS for 24 h, and then quantiﬁedmitochondrial motility in axons. The
average speed of mitochondrial movement was 12.1±1.8 µm/min. In
the Aβ25–35-treated cultures, we observed signiﬁcantly decreased total
mitochondrial motility (20.4±2.6% — mean±SE, Pb0.032) and mito-
chondria moving anterograde (10.1±2.6% — mean±SE, Pb0.016)
relative to the PBS vehicle-treated neurons. A decrease in retrograde-
moving mitochondria was also observed (10.3±1.5% — mean±SE) in
the Aβ25–35-treated neurons relative to the PBS vehicle-treated neurons.
However, this decrease did not reach statistical signiﬁcance (P=0.234).
The average speed of mitochondria undergoing the Aβ25–35 treatment
was only slightly decreased (10.9±1.9 μm/min —mean±SE, P=0.66)
compared to the mitochondria from the vehicle-treated neurons. In the
PBS vehicle-treated neurons, 36.4±4.7% (mean±SE) of the observed
mitochondria were motile, with 21.0±1.3% moving anterograde and
15.4±3.4% moving retrograde.
As shown in Fig. 1, the Aβ35–25-treated neurons (the controls) did
not show any change in total mitochondrial motility – neither
anterograde nor retrograde – relative to the PBS vehicle-treated
neurons, indicating that mitochondrial alterations are speciﬁc to
Aβ25–35.
3.2. Mitochondrial distribution is altered after Aβ treatment
Following our observations of the decrease in overall anterograde
mitochondrial motility, we examined whether Aβ treatment also
induced changes in mitochondrial distribution within neurites.
Cultures treated for 24 h with the PBS vehicle or the Aβ25–35 were
harvested, and the neuritic mitochondrial content was analyzed. We
found that Aβ treatment signiﬁcantly decreased the mitochondrial
index in neurons treated with Aβ relative to the PBS-treated (PBS,
40.1±3.1% — mean±SE; Aβ, 18.4±2.5% — mean±SE, Pb0.001)
(Figs. 2 and 3). We found the mitochondrial index did not change in
neurons treated with Aβ35–25 peptide, indicating that the decrease inthe mitochondrial index that we found in neurons treated Aβ25–35
peptide is, indeed, associated with Aβ.
The mitochondrial index reﬂects the total mass of mitochondria per
unit length of a neurite and can be affected by changes in either the
number or the size ofmitochondria.We therefore analyzedmitochondrial
length anddensity (thenumber ofmitochondria per length of neurite). As
shown in Fig. 2, the average mitochondrial length was signiﬁcantly
decreased in neurons with the Aβ peptide relative to the PBS-treated
neurons (PBS, 2.47±0.21 μm—mean±SE;Aβ, 1.37±0.10 μm—mean±
SE, Pb0.001) (Fig. 2). Mitochondrial density decreased from 17.3±0.9
mitochondria/100 µm in the PBS-treated neurons to 13.6±1.5mitochon-
dria/100 µm relative to the Aβ-treated neurons (P=0.054). Overall, we
found that mitochondrial mass was greatly reduced after receiving Aβ
treatment relative PBS vehicle treated control neurons, and that this effect
is largely due to decreasedmitochondrial size (Figs. 2 and 3). As shown in
Fig. 3, we found fragmentedmitochondria in DsRed labeled hippocampal
neurons treated with Aβ relative to PBS treated control neurons.3.3. Immunoreactivity of synaptic protein was less in Aβ25–35-treated
neurons
To determine the effect of Aβ25–35 treatment on the immunoreac-
tivity of synaptophysin and Drp1 in hippocampal neurons, we treated
neurons with Aβ25–35 and with PBS for 24 h, and then performed
immunostaining. As shown in Fig. 4, we found the immunoreactivity
of synaptophysin signiﬁcantly decreased, particularly at synapses in
those neurons treated with Aβ25–35 (54.2±5.9%, mean±SE, Pb0.013,
Fig. 4A), relative to the synapses in neurons treated with the PBS
vehicle (100±5.9%, mean±SE).
Fig. 2. Amyloid beta treatment causes a reduction in mitochondrial mass within neurites. Mitochondria from DsRed-mito transfected hippocampal neurons were analyzed after
vehicle, Aβ, or reverse peptide treatment. Mitochondrial index was calculated as the percent of neuritic length occupied by mitochondria. Aβ treated cultures showed pronounced
reduction in mitochondrial index (A). The distribution of mitochondria was evaluated as number of mitochondria per neuritic length (B). Mitochondrial length was reduced by Aβ
treatment (C). N=4 independent cultures. **pb0.01. Statistical variation is shown as mean±SE.
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double-labeling immunostaining analysis using synaptic marker,
MAP2 and Drp1 in neurons treated with Aβ25–35 and with PBS for
24 h. Similar to synaptophysin, immunoreactivity of MAP2 is
decreased in neurons treated with Aβ25–35 (Fig. 4A image E) relative
to PBS treated neurons (image B), indicating that Aβ25–35 peptidemay
be involved in synaptic degeneration.
To determine the effect of Aβ25–35 on mitochondria, particularly
mitochondria localized at synapses, we performed double-labeling
analysis of Drp1 (enriched in synapses) and Cyt. B (mitochondria-
encoded protein) antibodies. As shown in Fig. 5, we found
fragmented and punctuated immunoreactivity of Drp1 in neurons
treated with Aβ25–35 relative to the Drp1 immunoreactivity in
neurons treated with Aβ35–25 or the PBS vehicle (Fig. 5). Drp1
expression was higher in synapses, spines, and branches that were
developing in reverse Aβ peptide or PBS vehicle treated neurons,
whereas in Aβ25–35 peptide treated neurons, we found decreased and
fragmented immunoreactivity, particularly at synapses indicating
mitochondrial fragmentation, and degenerating synapses. Further,
Drp1 is colocalized with Cyt. B further conﬁrming that fragmented
immunoreactivity represents mitochondrial fragmentation caused
by Aβ25–35 peptide.
4. Discussion
In this study, we analyzed the effect of Aβ treatment on
mitochondrial motility and distribution in hippocampal neurons
from mice. We found mitochondrial motility greatly reduced by the
exposure of the hippocampal neurons to Aβ, and the reduction in
anterograde transport greater than the reduction in retrograde
movement. Overall, a reduction in mitochondrial transport in the
hippocampal neurons was observed and mitochondrial transport wasFig. 3.Mitochondria are more fragmented after Amyloid beta treatment. DsRed-mito transfe
Representative images are shown in upper panels. Enlargements of neurites are shown in timpaired in the distal regions of the neurites.We also found decreased
synaptic branching and growth in neurons treated with Aβ. This
would lead to decreased ATP production, followed by synaptic
dysfunction and degeneration. These ﬁndings lead us to conclude
that Aβ impairs axonal transport of mitochondria and may cause
synaptic degeneration.
4.1. Amyloid beta and impaired axonal transport of mitochondria
Aβ is generated in neurons, wherever APP and β- and γ-secretases
are present, which is in several intracellular sites, including Golgi
apparatus, endoplasmic reticulum, endosomal–lysosomal systems,
and multivesicular bodies. Recent studies of AD patients and
transgenic AD mice found intracellular Aβ present in AD-affected
brain regions and that Aβ1–42 participates in ﬁbrillogenesis and the
formation of Aβ plaques. Increasing evidence suggests that Aβ
accumulates in cellular compartments, including mitochondria, and
that Aβ interferewith normal functions ofmitochondria and synapses.
Findings from the present study help elucidate a mechanistic
relationship among Aβ, synaptic damage, and mitochondrial damage
in neurons affected by AD. We found a dramatic reduction (55%) in
the total mitochondria in hippocampal neurons exposed to Aβ, and
we found signiﬁcantly reduced anterogrademitochondrial movement
(cell body to synapses) in the Aβ-treated hippocampal neurons
relative to the PBS-treated neurons. We also found the length of
mitochondria signiﬁcantly decreased in the Aβ-treated hippocampal
neurons compared to the PBS-treated or the Aβ35–25-treated hippo-
campal neurons. Finally, we found the immunoreactivity of synapto-
physin signiﬁcantly decreased in the Aβ-treated neurons, compared
to the PBS-treated hippocampal neurons.
Reductions in the total number of mitochondria and of antero-
grade-moving mitochondria are likely responsible for the synapticcted hippocampal neurons were imaged after vehicle, Aβ, or reverse peptide treatment.
he lower panels.
Fig. 4. Double-labeling analysis of Synaptophysin and MAP2 in neurons treated with amyloid beta. Hippocampal neurons treated with PBS vehicle or Aβ were immunostained for
synaptophysin and MAP2 (A). Vehicle treated cells (upper panel) showed typical strong synaptophysin (a), MAP2 (b) immunoreactivities and colocalization of synaptophysin and
MAP2 (c). Aβ-treated cells (lower panel) showed reduced density of synaptophysin puncta (d), MAP2 (e) and merged (f). Image B shows quantiﬁcation of synaptophysin
immunoreactivity. Signiﬁcantly decreased synaptophysin was found in Aβ-treated neurons (Pb0.005). Image C shows enlarged portion of a neurite from PBS vehicle treated neuron
(a) and Aβ-treated neuron (b).
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healthy and functionally active mitochondria are necessary for ATP
production at synapses where energy-demand is high. Reduction in
anterograde-moving mitochondria appears to reduce the supply of
ATP at synapses, which may cause synaptic degeneration that marks
AD neurons. Our ﬁnding pointing to Aβ-induced impaired mitochon-
drial transport is consistent with other studies showing decreased
mitochondrial transport [23,35,36] and organelle transport [37–39] in
Aβ-treated neurons.
Wang et al. [23] reported that Aβ oligomer (ADDLs)-treated
hippocampal neurons from mouse showed signiﬁcantly reduced
mitochondrial anterograde (0.80±0.67) and retrograde axonal
transport (0.44±0.21), compared to hippocampal neurons not so
treated (5.34±0.47 for anterograde and 3.31±0.02 for retrograde
transport). Neurons treated with Aβ42–1 exhibited a fast axonalFig. 5. Drp1 distribution relocates from areas of active neurite outgrowth to neuritic proces
were immunostained for Drp1, mitochondrial-encoded protein, Cyt. B and nuclear marker, D
Cyt. B (B), DAPI (C) and merged (D) in neurite growth cones (white arrows). Drp1 is colocal
reduced (E), and Drp1 is colocalized with mitochondria in merged image (H).transport of mitochondria that was similar to the axonal transport
found in the control neurons.
Du and colleagues [36] found a 30% increase in the percentage of
stationary mitochondria in Aβ-treated neurons relative to mitochon-
dria in untreated neurons. Further, the total number of mitochondria
moving in both directions (anterograde and retrograde) was
signiﬁcantly reduced in the Aβ-treated neurons compared to those
treated with the PBS vehicle or the control (Aβ42–1 treated). After Aβ
treatment, the anterograde moving mitochondria decreased by ∼23%
compared to those in the PBS-treated neurons and in the control
neurons (Pb0.05). In contrast, the percentage of retrograde mobile
mitochondria increased those neurons treated with Aβ1–42.
The velocity of mitochondrial motility was also less in neurons
treated with Aβ relative to that of the PBS-treated neurons, indicating
that Aβ affects mitochondrial velocity. Our ﬁndings are consistentses after amyloid beta treatment. Hippocampal neurons treated with PBS vehicle or Aβ
API. Vehicle treated cells (upper panel) showed intense immunoreactivities of Drp1 (A),
ized with Cyt. B (D) (white arrows). After Aβ treatment (lower panel), Drp1 staining is
512 M.J. Calkins, P.H. Reddy / Biochimica et Biophysica Acta 1812 (2011) 507–513with those from Du et al. [34], who also reported signiﬁcantly reduced
mitochondrial anterograde velocity in neurons treated with Aβ1–42
relative to control and Aβ42–1-treated neurons.
Overall, ﬁndings from our study, together with those fromWang et
al. [23] and Du et al. [36], indicate that the Aβ peptide is toxic and
impairs axonal transport of mitochondria. Further, our ﬁndings are
consistent with ﬁndings from other mitochondrial trafﬁcking studies
by Chang et al. [40] and Rui et al. [35], reporting that mitochondrial
transport and distribution were affected by hippocampal neurons
exposed to the Aβ peptide, glutamate and zinc.
By shifting the balance of anterograde/retrograde transport
toward retrograde, a decrease in axonal and neuritic mitochondria
would be expected. Indeed, we observed this effect, ﬁnding a large
reduction in mitochondrial mass in the Aβ-treated cells (Fig. 2); more
speciﬁcally, we found the average length of mitochondria length was
decreased, but the total number of mitochondria per each length was
less affected. These ﬁndings suggest that factors dictating mitochon-
drial distribution along an axon are unaffected by Aβ treatment.
However, mitochondrial dynamics are likely shifted toward ﬁssion.
4.2. Amyloid beta and abnormal mitochondrial dynamics
We [32] and others [21,22] reported increased mitochondrial
ﬁssion and decreased fusion in neurons affected by AD. In other
words, abnormal mitochondrial dynamics occurs in neurons affected
by AD. This may be due to the association of Aβ with mitochondria.
Mitochondrial Aβ is known to induce free radical production and to
activate the ﬁssion proteins Drp1 and Fis1, and to fragment
mitochondria [32]. When mitochondrial ﬁssion is activated, fusion
proteins decrease.
Our immunostaining analysis of Drp1 showed fragmented and
punctuated immunoreactivity in Aβ-treated neurons, indicating
increased mitochondrial ﬁssion and decreased fusion. As described
elsewhere [32], in Aβ-treated neurons, mitochondrial fusion is
reduced following the induction of apoptosis. Over-expression of
mitofusins can reduce apoptosis. Further, it has been previously
suggested that mitochondrial fusion and transport are closely linked,
such that disruptions in either process affect the other. Recently,
Miskow et al. [41] showed that Mfn2 interacts with the Miro-Milton
complex, and this interaction is required for axonal transport of
mitochondria in dorsal root ganglia neurons. Conversely, mitochon-
drial fragmentation induced by Pink1 knockdown can be rescued by
the overexpression of Miro or Milton [42]. In this light, it is not
surprising that we observed both altered mitochondrial transport and
altered mitochondrial dynamics.
4.3. Decreased synaptic growth in Aβ-treated neurons
Our quantitative analysis of synaptophysin immunoreactivity
revealed that synaptophysin was signiﬁcantly decreased in Aβ-
treated neurons, indicating that Aβ affects synaptic growth, an
observation supported by other studies [43–46]. Further, MAP2
immunoreactivity was decreased in Aβ-treated neurons, further
supporting that synaptic degeneration is present in Aβ-treated
neurons. This reduced synaptic growth was primarily due to the
decrease mitochondrial trafﬁcking, particularly the anterograde
movement of mitochondria, which is known to ultimately lead to
the production of ATP at synapses and to the degeneration of synapses
in AD neurons.
In summary, we found reduced mitochondrial mass, reduced
mitochondrial motility, and reduced mitochondrial anterograde
transport in neurons exposed to the Aβ25–35 peptide. We also found
a reduction in the number of mitochondria in distal regions of neurons
and decreased synaptic branching and growth in the Aβ-treated
neurons. These ﬁndings lead us to conclude that Aβ impairs axonal
transport of mitochondria and may cause synaptic degeneration.Acknowledgements
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